Inactivated PCV2 one shot vaccine applied in 3-week-old piglets: Improvement of production parameters and interaction with maternally derived immunity

Fraile, Lorenzo; Grau‐Roma, Llorenç; Sarasola, P.; Sinovas, Nuria; Nofrarías, Miquel; López-Jiménez, R.; López-Soria, Sergio; Sibila, Marina; Segalés, Joaquím

doi:10.1016/j.vaccine.2012.01.008

Cited by 72 publications

(59 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have no clear explanation for these differences in the induction of protective immunity and the reduction of PCV2 viremia; however, they may be due to the different types of antigens and adjuvants among the 4 PCV2 vaccines (9). Nevertheless, the 4 commercial PCV2 vaccines used in this study were shown to be efficacious in controlling PCV2 infection under experimental conditions (10,19,20,22,24) and PCVAD under field conditions (16,23,25,26). Hence, further studies may be needed to determine the clinical significance of different levels of PCV2 viremia in pigs vaccinated with different commercial PCV2 vaccines in the finishing period.…”

Section: Discussionmentioning

confidence: 72%

Comparison of Four Commercial One-Dose Porcine Circovirus Type 2 (PCV2) Vaccines Administered to Pigs Challenged with PCV2 and Porcine Reproductive and Respiratory Syndrome Virus at 17 Weeks Postvaccination To Control Porcine Respiratory Disease Complex under Korean Field Conditions

Park

Seo

Han

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Under Korean field conditions, coinfection with porcine circovirus type 2 (PCV2) and porcine reproductive and respiratory syndrome virus (PRRSV) is most commonly observed in porcine respiratory disease complex (PRDC). Despite the wide use of PCV2 vaccination, PRDC remains a serious respiratory problem. Thus, the objective of this study was to determine and compare the efficacy of 4 one-dose PCV2 vaccines on 3-week-old pigs with an experimental PCV2-PRRSV challenge at 17 weeks postvaccination. Regardless of which commercial PCV2 vaccine was used, the vaccination of piglets at 3 weeks of age was efficacious against cochallenge of PCV2 and PRRSV, on the basis of growth performance and PCV2-associated lesions. However, the inactivated chimeric PCV1-2 and the PCV2 vaccines induced higher PCV2-specific neutralizing antibody (NA) titers and PCV2-specific gamma interferon-secreting cells and lower PCV2 viremia levels than the two PCV2 subunit vaccines. The vaccination of piglets against PCV2 at 3 weeks of age was effective in reducing PCV2 viremia and PCV2-associated lesions during the finishing period, which is an age at which pigs are frequently affected by PRDC caused by coinfection with PCV2 and PRRSV under Korean field conditions.

show abstract

Section: Discussionmentioning

confidence: 72%

Comparison of Four Commercial One-Dose Porcine Circovirus Type 2 (PCV2) Vaccines Administered to Pigs Challenged with PCV2 and Porcine Reproductive and Respiratory Syndrome Virus at 17 Weeks Postvaccination To Control Porcine Respiratory Disease Complex under Korean Field Conditions

Park

Seo

Han

et al. 2014

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

show abstract

“…Vaccination schedules at earlier ages with one single dose are rarely applied, since high levels of maternally derived antibodies (MDA) at the vaccination time may cause a lower humoral immune response (interference with the seroconversion) elicited by the vaccine [6, 11, 28, 29] and may eventually jeopardize the efficacy of vaccination [8, 30]. …”

Section: Discussionmentioning

confidence: 99%

Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages

Oliver-Ferrando

Segalés

López-Soria

et al. 2016

Vet Res

Self Cite

View full text Add to dashboard Cite

This study aimed to determine the porcine circovirus type 2 (PCV2) serological and virological dynamics in piglets vaccinated at different ages in a PCV2 subclinical infection (PCV2-SI) scenario. Six hundred and forty-four 2 week-old healthy piglets were selected and distributed into four treatment groups: vaccination at 3, 6 or 10 weeks of age (3W-VAC, 6W-VAC and 10W-VAC groups, respectively) and unvaccinated pigs (NON-VAC group). Blood (n = 112 pigs) and oral fluid (OF) (n = 40 pens) samples were taken throughout the study to assess PCV2 load, humoral immunity and viral genotyping. Percentage of PCV2-DNA positive sera mainly raised by 10 weeks of age, being maximum at 14 weeks of age, and then started to decrease at 18 and 25 weeks of age. Specifically, PCV2 vaccination at 3 or 6 weeks of age yielded similar results, since they produced an earlier seroconversion and reduced, at different sampling points, the proportion of viremic animals in comparison to the unvaccinated group. In contrast, PCV2 vaccination at 10 weeks of age only achieved such reduction at 25 weeks of age; in this case, vaccination coincided with the increase of the percentage of viremic pigs in the population. Both serological techniques used in sera and OF offered similar results with a high and statistically significant correlation. In contrast, a higher percentage of PCV2 DNA positivity was detected in OF in comparison with sera. In conclusion, under the present study conditions, the optimal time for PCV2 piglet vaccination was at either 3 or 6 weeks of age.

show abstract

“…The subunit vaccines are the PCV2 capsidbased subunit vaccines expressed in a Baculovirus vector with high cost. Currently, the commercially inactivated whole virus versus subunit vaccines cause low antibody levels, and the duration of immunity available ranges from 4 to 6 months (12,21,30). Multi-immunization is therefore required to achieve a lasting and efficient immunity response, which increases the cost for farms (9,26).…”

mentioning

confidence: 99%

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Chen

Wang

et al. 2014

Viral Immunology

View full text Add to dashboard Cite

In this study, two recombinant plasmids containing the ORF2 gene of porcine circovirus type 2 (PCV2) with or without porcine interleukin-18 (IL-18) were constructed and evaluated for their ability to protect piglets against PCV2 challenge. Transient expression of the plasmids in PK-15 cells could be detected using Western blot. Piglets were given two intramuscular immunizations 3 weeks apart and were challenged with a virulent Wuzhi strain of PCV2 at 42 days after the initial immunization. All animals vaccinated with pBudCE4

show abstract

Inactivated PCV2 one shot vaccine applied in 3-week-old piglets: Improvement of production parameters and interaction with maternally derived immunity

Cited by 72 publications

References 29 publications

Comparison of Four Commercial One-Dose Porcine Circovirus Type 2 (PCV2) Vaccines Administered to Pigs Challenged with PCV2 and Porcine Reproductive and Respiratory Syndrome Virus at 17 Weeks Postvaccination To Control Porcine Respiratory Disease Complex under Korean Field Conditions

Comparison of Four Commercial One-Dose Porcine Circovirus Type 2 (PCV2) Vaccines Administered to Pigs Challenged with PCV2 and Porcine Reproductive and Respiratory Syndrome Virus at 17 Weeks Postvaccination To Control Porcine Respiratory Disease Complex under Korean Field Conditions

Evaluation of natural porcine circovirus type 2 (PCV2) subclinical infection and seroconversion dynamics in piglets vaccinated at different ages

Immune Responses of Piglets Immunized by a Recombinant Plasmid Containing Porcine Circovirus Type 2 and Porcine Interleukin-18 Genes

Contact Info

Product

Resources

About